The reversal of cisatracurium induced neuromuscular block using the subjective neuromuscular monitoring

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0000139

Enrollment

Registered

2011-07-05

Start date

2011-06-06

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Others : Cisatracurium 0.15mg/kg is adminitered iv. to every patient of all groups when we induced him or her, and Neostigmine 0.07mg/kg, glycopyrrolate ivs. 0.014 mg/kg is used for reversal of muscle

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 18-64 yrs old, ASA 1,2

Exclusion criteria

Exclusion criteria: Body weight over 130% of IBW, musculoneuronal disease, drug that can affect on neunomuscular transmission. Renal or hepatic disease, cardiac pacemaker

Design outcomes

Primary

Measure	Time frame
Time from reversal of relaxation to train-of-four (TOF) ratio 0.9	—

Secondary

Measure	Time frame
Time from reversal of relaxation to train-of-four (TOF) ratio 0.7, 0.8.	—

Countries

Korea, Republic of

Contacts

Public ContactIn-ae Song

Seoul National University Bundang Hospital

Outcome results